Strategic collaborations IRB Barcelona operates at the intersection of biomedical research and clinical translation with multiple spin-off companies and a track record of bringing discoveries to the clinic. This presents opportunities for strategic partnerships in joint research, co-development of therapeutics, and access to translational platforms that can accelerate customer pipelines.

Spin-off funnel The institute has multiple spin-offs (including HelixAI, Nuage Therapeutics, Inbiomotion, Nostrum Biodiscovery, Ona Therapeutics) that translate research into market-ready solutions. Targeting these spin-offs with discovery services, data analytics, or early-access collaborations can unlock mutual growth and early commercial traction.

Technology stack IRB Barcelona employs a modern tech ecosystem (Grafana, GATK, cloud/CDN, GAMESS, cloud and identity tools) indicating a mature research IT environment. There is potential for selling computational biology, cloud-hosted data platforms, AI-assisted drug discovery, and cybersecurity/compliance offerings tailored to regulated biomedical research.

Funding & growth With revenue in the tens of millions and active funding streams plus ongoing spin-off activity, IRB Barcelona appears to be in a growth phase with appetite for expanding capabilities, pilot projects, and scale-up collaborations that could translate into long-term service agreements.

Knowledge network As a Severo Ochoa Centre of Excellence and a hub within the Barcelona Institute of Science and Technology, IRB Barcelona hosts high-profile symposia and international collaborations. This provides access to a broad network of researchers and potential customers, ideal for sponsorships, executive briefings, and co-sponsored events to generate leads.